Niklas Czeloth

Chairman of the Board (Interim)

2023 - Current

Director Board of Directors

2023

Chairman of the Board (Interim)

2023

Director Board of Directors

2023

Member of Boehringer Ingelheim´s Immunogenicity Expert Panel

2014

Executive Director / Investment Manager - Boehringer Ingelheim Venture Fund

2020

Interest in early investment opportunities in immuno-oncology, regenerative medicine and anti-infectives. (Please describe scope of interaction in contact requests. Thank you!)

International Project Leader (Oncology, Retinopathy, CNS projects)

2018 - 2020

Project leadership for global drug development projects

Director / Head of Biosciences (Nonclinical / DMPK / Pharmacology) Biosimilars

2014 - 2018

Head of Bioanalysis/DMPK Biosimilar Programs Heading of non-clinical activities for Biosimilars Portfolio Serving as Head of Nonclinical for Biosimilar projects Pharmacology / Toxicology activities for the Biosimilars Business

Project Manager DMPK Biosimilars

2013 - 2014

Pharmacokinetics of monoclonal antibodies (biosimilarity trials, population PK) Responsibility for Bionalysis/DMPK (PK, ADA, nAb assays) Pharmacology of monoclonal antibodies (SPR, CDC, ADCC, effector functions, FcR, glycosylation) Immunogenicity Toxicological studies Translational research/devlopment Regulatory agenciy interactions

Director Board of Directors

2020 - 2021

Leiter Pharmakologie Biotherapeutika

2008 - 2013

Associate Director Pharmacology Biotherapeutics. Expertise Preclinical Development, Immunology, ICH Guidelines, IMPD/IND preparation, Toxicology, PK/PD, Project management, Monoclonal Antibodies, Biotherapeutics, Flowcytometrie, Research Tregs, Collaboration Management.

Scientist

2003 - 2007

Scientist Immunology Basic Research Dendritic cells, T cells, Tregs, B cells, Cell Trafficking, S1P signalling. Expertise FACS, cell sorting, Immunofluorescence, Antibody production, labelling.basic immunology, RT-PCR.